BioNTech mRNA Cancer Vaccine Trial Termination

BioNTech's personalized mRNA cancer vaccine

trial has just been terminated over an alarming

mortality signal. Their own data safety monitoring board

found an imbalance in overall survival between the treatment

groups. Now, the concerning thing is, is they didn't

disclose, uh, just how much-- how big that

mortality imbalance was. So we don't know exactly how many more

people

died in the mRNA group who actually received up to

fifteen doses, up to fifteen

IV mRNA doses in the treatment

group. So they were hyper-dosed. These patients all had,

you'll see at the top corner, uh, colon cancer stage two to

three. The tumors were resected, so they removed the

tumors, and then they administered up to fifteen,

uh,

mRNA doses. And, uh, clearly, it didn't work

whatsoever. And the group that didn't get any mRNA, uh,

fared most likely much better, and, uh,

they, uh, did not die as quickly. And so this just goes to show just

how bad, uh, mRNA technology is. It does not

work. It doesn't work for cancer. It doesn't work for flu.

It doesn't work for RSV, and it doesn't work for COVID.

And so this is just another stark reminder that, uh, we have

to retire and end the mRNA

platform for all of these diseases as this unchecked

expansion, uh, continues to grow.

And so this is a big hit against the vaccine cartel.